Pfizer to buy prostate cancer drug maker Medivation for $14 billion
Monday, August 22, 2016 - 07:01
in Mathematics & Economics
Ed AdamczykNEW YORK, Aug. 22 (UPI) -- Pfizer Inc. announced the $14 billion purchase of Medivation Inc., makers of the prostate cancer drug Xtandi.
